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Background: Acute exacerbation (AE) is currently established as a distinct condition with acute
deterioration of respiratory status in idiopathic pulmonary fibrosis (IPF). Recently, several
studies have reported that AE also occurred in interstitial pneumonias other than IPF, such
as collagen vascular disease-associated interstitial pneumonia (CVD-IP). However, the inci-
dence of AE in CVD-IP and its clinical characteristics remain to be fully determined. This study
was conducted to elucidate cumulative incidence of AE in CVD-IP and its clinical features.
Methods: We reviewed 83 biopsy-proven CVD-IP patients, estimated cumulative incidence of
AE, and examined its clinical characteristics.
Results: Among 83 CVD-IP patients, six patients with a mean age of 65.7 years developed AE
(overall incidence, 7.2%; 1-year incidence, 1.25%). Underlying CVDs included rheumatoid
arthritis (RA) (nZ 5; overall incidence, 20.0%) and primary Sjo¨gren syndrome (nZ 1; overall
incidence, 5.9%). Patients with AE showed acute respiratory deterioration with severe hypox-
emia (mean PaO2/FiO2 ratio, 131). Radiologically, ground-glass opacity was superimposed on
the underlying reticular abnormalities. Preexisting histological patterns included three usual
interstitial pneumonia (UIP) and two non-specific interstitial pneumonia (NSIP). Five (83.3%)
of six patients died of respiratory failure despite intensive therapy. Univariate Cox’satomyositis; CVD, collagen vascular disease; DM, dermatomyositis; MCTD, mixed connective tissue
pneumonia; PM, polymyositis; pSS, primary Sjo¨gren syndrome; RA, rheumatoid arthritis; SLE, systemic
ual interstitial pneumonia.
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Acute exacerbation of collagen vascular diseases 847proportional hazards analysis showed that age and RA diagnosis were significantly associated
with AE. Multivariate Cox’s proportional hazards analysis indicated that age was an indepen-
dent significant factor predicting AE.
Conclusions: These data suggest that AE can occur in CVD-IP, and this condition is closely
similar to that of IPF with poor prognosis. AE is most common in RA, and associated with higher
ages.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
In idiopathic pulmonary fibrosis (IPF), acute exacerbation
(AE) has been increasingly recognized as an acute, often
fatal, clinical incident, which occurs during the course of
this disease.1e6 Much effort has been devoted to charac-
terize this condition, and most recently the Idiopathic
Pulmonary Fibrosis Clinical Research Network (IPF net) have
proposed a definition and criteria for AE of IPF.6 In IPF, AE is
characterized by rapid worsening of respiratory symptoms,
acute deterioration of hypoxemia, newly developed bilat-
eral ground-glass opacity and/or consolidation on chest
radiographs or computed tomography (CT) scans, and the
absence of other alternative causes, such as infection,
heart failure and embolism.5,6 Histologically, diffuse alve-
olar damage (DAD) is superimposed on the underlying
fibrotic pattern of usual interstitial pneumonia (UIP) in
most patients with AE of IPF.1,2,7,8
Recently, AE has also been shown to occur in interstitial
pneumonias other than IPF, such as idiopathic non-specific
interstitial pneumonia (NSIP) and collagen vascular disease-
associated interstitial pneumonia (CVD-IP).9e14 Parambil
et al. have reported AE in three of 18 patients with primary
Sjo¨gren syndrome-associated interstitial pneumonia (pSS-
IP).11 More recently, Park et al. have described this condi-
tion in four of 93 patients with CVD-IP.13 To date, however,
the cumulative reported number of CVD-IP patients with AE
is small, and the incidence of this condition in CVD-IP, and
its clinical characteristics, remain to be fully determined.
Thus, the present study was conducted to estimate cumu-
lative incidence of AE in CVD-IP, and to establish its clinical
features.
Patients and methods
Patients
The study population included 83 consecutive patients (35
males and 48 females) with CVD-IP who underwent open or
thoracoscopic lung biopsy in our facilities from 1987 to
2007. Each CVD was diagnosed according to established
criteria.15e20 A diagnosis of amyopathic dermatomyositis
(ADM) was based on modified Euwer’s criteria in our
previous study21: (1) characteristic dermatological mani-
festations of classic dermatomyositis (DM), including
a heliotrope rash and Gottoron’s papules; (2) no muscle
weakness; (3) no increase in serum muscle enzymes during
the observation period. AE was defined using the criteria
recently proposed by the IPF net, with slight modification
for adaptation to CVD-IP6: (1) previous diagnosis of CVD-IP;
(2) unexplained worsening or development of dyspnea
within 30 days; (3) high-resolution CT (HRCT) with newbilateral ground-glass abnormality and/or consolidation
superimposed on a background reticular or honeycomb
pattern; (4) no evidence of pulmonary infection by negative
respiratory culture, including endotracheal aspirate or
bronchoalveolar lavage, and serological test results for
respiratory pathogens; and (5) exclusion of alternative
causes, such as left heart failure, pulmonary embolism, and
an identifiable cause of acute lung injury. Patients with AE
needed to meet all five criteria. The study protocol was
approved by the Ethical Committee of the Hamamatsu
University School of Medicine.
Data collection
Clinical data were obtained from medical records. Labo-
ratory findings and pulmonary function tests at the time of
surgical lung biopsy and AE, and outcome were also
recorded.
Pathological review
Biopsy specimens were obtained from at least two sites.
Lung biopsy specimens were independently reviewed by
three pathologists (T.V.C, Y.N., S.I.) who were unaware of
the clinical or physiological findings. When classification
differed between the pathologists (kappa coefficient of
agreementZ 0.40), a consensus opinion on the overall
histopathological pattern was reached. Histological classi-
fication was based on the previously published criteria for
idiopathic interstitial pneumonias from the American
Thoracic Society (ATS)/European Respiratory Society (ERS)
consensus statement.22 A histological pattern that could
not be placed in any patterns described in the consensus
statement was categorized as unclassifiable interstitial
pneumonia. Sections stained with hematoxylineeosin were
reviewed from all cases, and sections in which elastic tissue
was stained were reviewed in selected cases.
HRCT
HRCT findings were reviewed by a radiologist (Y.T.) and two
pulmonologists (T.S., N.I.), without knowledge of any clin-
ical data. HRCT examination of the lungs was performed on
1.0- or 1.5-mm thick sections to evaluate radiographic
abnormalities.
Bronchoalveolar lavage
BAL findings were retrospectively reviewed. BAL was per-
formed as described previously.23 Briefly, a fiberoptic
bronchoscope was passed transorally and wedged in
a segmental or subsegmental bronchus of the middle lobe.
Table 1 Clinical characteristics of CVD-IP at initial
presentation.
Number of patients
or values
Sex, male/female 35/48
Age, years 58.7 9.5a
Smoking habit
Current/ex-smoker/never 24/6/53
Underlying collagen
vascular diseases
RA 25
PM/DM/ADM 21
pSS 17
SSc 13
SLE 4
MCTD 2
Adult Still’s disease 1
Histological pattern
NSIP 50 (60.3%)
UIP 30 (36.1%)
Unclassifiable 3 (3.6%)
Observation periods, years 6.0 5.6
Laboratory data
%VC (nZ 83) 82.9 17.9
DLco, % (nZ 78) 75.0 25.6
PaO2 on room
air, Torr (nZ 83)
79.8 9.8
KL-6, U/ml (nZ 63) 1003 1642
Treatment for interstitial pneumonia
Corticosteroid, % 65.0
Immunosuppressant, % 22.9
RA, rheumatoid arthritis; SSc, systemic sclerosis; pSS, primary
Sjo¨gren syndrome; PM, polymyositis; DM, dermatomyositis;
ADM, amyopathic dermatomyositis; SLE, systemic lupus eryth-
ematosus; MCTD, mixed connective tissue disease; NSIP, non-
specific interstitial pneumonia; UIP, usual interstitial
pneumonia.
a mean SD.
848 T. Suda et al.Three 50-ml aliquots of sterile 0.9% saline were instilled and
the returns were gently aspirated through the side channel
of the bronchoscope. BAL fluid (BALF) was centrifuged at
800g for 10 min to obtain the cellular components. The total
cell count was determined using a hemocytometer and
a differential cell count was taken on Giemsa-stained cyto-
centrifuged preparations.
Statistical analysis
For two group comparisons involving binary data, we used
either the chi-square test or Fisher’s exact test, depending
on expected frequencies. The cumulative incidence of AE in
CVD-IP patients was estimated using KaplaneMeier curves.
The overall incidence was calculated by dividing the
number of patients developing AE during the observation
periods by the total number of patients. Cox proportional
hazards regression analysis was used to identify significant
variables associated with AE. Statistical analyses were
performed using JMP Start Statistics (SAS Institute Inc., NC,
USA). The p value <0.05 was considered significant. All data
are expressed as a mean SD.
Results
Incidence of AE in CVD-IP
The clinical characteristics of 83 CVD-IP patients proven by
surgical lung biopsy at the initial presentation are shown in
Table 1. During the observation period, six patients (7.2%)
developed AE with a 1-year incidence of 1.25% (Table 2;
Fig. 1). There were four males and two females. Among the
underlying CVDs, AE was found in rheumatoid arthritis (RA)
and primary Sjo¨gren syndrome (pSS) (Table 2). The overall
and 1-year incidence of AE were highest in RA (20.0 and
2.58%, respectively), followed by pSS (5.9 and 1.05%,
respectively). No AE occurred in patients with CVDs other
than RA and pSS (Table 2). With regard to histological
patterns, patients with UIP showed higher frequency of AE
than those with NSIP (overall incidence, 10.0 vs. 4.0%;
1-year incidence, 2.00 vs. 0.70%, respectively) (Table 2).
There was no significant difference in the observation
periods for the underlying CVDs, or histological patterns
(data not shown).
Clinical features
The clinical characteristics of six patients with AE of CVD-IP
are listed in Table 3. The age at the onset of AE was
65.7 5.3 years. All patients presented with rapidly dete-
riorating respiratory symptoms, such as dyspnea and cough,
within 30 days (18.3 8.3 days). Four patients (66.7%) had
fever, and fine crackles were present in all patients. The
duration between diagnosis of interstitial pneumonia and
onset of AE varied widely, with a mean of 66.5 months. One
patient (Case 6) developed AE after surgical lung biopsy. In
all six patients, the activity of the underlying CVD was
stable before the onset of AE. Low-dose corticosteroids
were given to one patient, and there were no alterations of
medications within 3 months before the onset of AE in any
patients.Laboratory and BAL findings
All patients had severe hypoxemia on admission for AE. The
P/F ratio (PaO2/FiO2 ratio) was 131 78 (Fig. 2). Serum
levels of C-reactive protein (CRP) and lactate hydroxygenase
(LDH) were markedly increased in all patients (CRP,
20.1 9.4 mg/ml; LDH, 571 249 IU/L) (Fig. 2). Addition-
ally, an elevation of serum KL-6 (normal range, <500 U/ml),
a marker of interstitial pneumonia, was found in all five
patients tested (1926 1045 U/ml) (Fig. 2). BAL was per-
formed in one patient (Case 4), and this analysis showed an
increase in total cell counts, as well as neutrophilia (total
cell count, 2.5 106 cells/ml BAL fluid; neutrophils, 64.0%).
Microbiological examination
Microbiological studies of BAL fluid (nZ 1), endotracheal
aspirates (nZ 5), sputum (nZ 6) and blood (nZ 6)
revealed no infectious agents, including bacteria,
Table 2 Incidence of AE in CVD-IP and its association with histological patterns.
Total
(nZ 83)
RA
(nZ 25)
pSS
(nZ 17)
SSc
(nZ 13)
PM/DM/ADM
(nZ 21)
SLE
(nZ 4)
Othersa
(nZ 3)
No. of patients
developing AE
6 (7.2%) 5 (20.0%) 1 (5.9%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Histologic patterns
UIP 3/30b (10.0%) 2/10 (20.0%) 1/10 (10.0%) 0/5 (0%) 0/3 (0%) 0/2 (0%)
NSIP 2/50 (4.0%) 2/13 (15.4%) 0/7 (0%) 0/8 (0%) 0/18 (0%) 0/2 (0%) 0/2 (0%)
Unclassifiable 1/3 (33.3%) 1/2 (50.0%) 0/1 (0%)
AE, acute exacerbation.
a Others include MCTD and adult Still’s disease.
b Number of patients developing AE / total number of patients showing each histological pattern.
Figure 1 Cumulative incidence of AE in CVD-IP.
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of serological studies for atypical pathogens, such as
Mycoplasma or Chlamydophila spp., were negative in all
patients. In three patients, serum titers of viruses,
including influenza viruses, parainfluenza viruses, respira-
tory syncytial viruses, rhinovirus, and coronaviruses, were
measured, and no significant elevation of any virus titer was
found. Three patients underwent a test for urinary antigens
of Legionella spp. (Binax Now, Binax, Scarborough, ME,
USA), which revealed a negative result in all patients.
HRCT and histological findings
The most conspicuous finding of HRCT at the onset of AE
was newly developed bilateral ground-glass opacity (100%),
with or without areas of consolidation, superimposed on
the bibasilar reticular abnormalities (Fig. 3). Patchy air
space consolidation was present in five patients (83.3%).
Four patients with AE underwent contrast-material
enhanced CT, which revealed no evidence of pulmonary
embolism. As a result of severe respiratory failure on
admission, the second surgical lung biopsy could not be
performed at the onset of AE in any patients. Autopsy was
performed in one patient (Case 4), which showed a DAD
pattern superimposed on the background of NSIP (Fig. 4).
Treatment and outcome
Intravenous bolus of methylprednisolone, 1000 mg once
a day for 3 days, was given to all patients, followed by
1 mg/kg/day prednisolone (Table 3). Four patients were
intravenously administered 500e750 mg/m2 cyclophospha-
mide. In addition, two patients received 2e3 mg/kg/day
cyclosporine. Despite these intensive anti-inflammatory
and immunosuppressive therapies, all patients required
mechanical ventilation, and five (83.3%) of them died of
respiratory failure. Among these five patients, four died
within 40 days after the onset of AE (26.0 11.6 days). One
patient survived (Case 5); his respiratory status had wors-
ened before the onset of AE, and he received supplemental
oxygen therapy after discharge.
Associated factors with AE development
To determine the associated factors with AE development
at the initial diagnosis, we first assessed the valuables byunivariate Cox’s proportional hazards regression models.
The variables included sex, age, smoking history, CVD
diagnosis, histologic patterns, pulmonary function test
results, laboratory findings, and arterial blood gas analysis
at the initial diagnosis. Among the valuables, age and RA
diagnosis were significantly associated with AE develop-
ment (Hazard Ratio 1.181 and 2.536, pZ 0.0037 and
pZ 0.0484, respectively) (Table 3). Moreover, multivariate
Cox’s proportional hazards regression models, including
those two valuables, showed that age was an independent
significant factor for AE development (Hazard Ratio 1.221,
pZ 0.0052) (Tables 4 and 5).
Discussion
The present study reviewed 83 patients with biopsy-proven
CVD-IP, and demonstrated AE in six patients (7.2%) during
the observation period. The incidence of AE in CVD-IP was
confirmed as 7.2% overall and 1.25% at 1 year, and this
condition occurred mostly in patients with RA. The clinical
characteristics of AE of CVD-IP were similar to those of IPF
with high mortality (83.3%). These data suggest that AE can
occur in CVD-IP with poor prognosis.
Recently, it has been recognized that IPF patients
present with acute clinical deterioration, termed as AE of
IPF.1e6 According to the IPF net criteria, with slight modi-
fication, we found six patients with AE in our series of 83
CVD-IP patients undergoing surgical lung biopsy. Typically,
Table 3 Clinical characteristics of patients with AE of CVD-IP.
No. Underlying
disease
Age (years),
sex
Smoking
status
Histological
pattern
Duration
between
diagnosis
of IP and
AE, months
Activity of
underlying
CVD at AE
Treatment
before AE
Treatment
for AE
Outcome
1 RA 57, female Former UIP 99 Stable Bucillamine MPSL, PSL CPA, CsA Died
2 RA 63, male Current UIP 86 Stable Mizoribine MPSL, PSL CPA Died
3 RA 65, male Former NSIP 129 Stable PSL
(10 mg/day)
PSL Died
4 RA 68, male Former NSIP 31 Stable Bucillamine MPSL, PSL CPA Died
5 RA 69, male Current Unclassifiable 52 Stable Bucillamine MPSL, PSL Survived
6 pSS 72, female Never UIP 2 Stable None MPSL, PSL CPA, CsA Died
IP, interstitial pneumonia; AE, acute exacerbation; PSL, prednisolone; MPSL, methylprednisolone; CPA, cyclophosphamide; CsA,
cyclosporine.
850 T. Suda et al.these six patients had acute respiratory deterioration
within 30 days. Their HRCT scan revealed bilateral ground-
glass opacity with or without air space consolidation
superimposed on preexisting reticular abnormality. The
results of extensive microbiological studies, such as trachea
aspirates and BAL, were negative. They responded poorly
to intensive therapy with high mortality rate. Collectively,
the features of our CVD-IP patients closely fitted those of
AE of IPF in the literature.1e6 To date, there have been
a few studies about AE in series of CVD-IP patients.9,11,13
Recent studies by Parambil et al. and Park et al. have
independently demonstrated AE of CVD-IP in three of 18
biopsy-proven pSS-IP patients and in four of 93 biopsy-
proven CVD-IP patients, respectively.11,13 Additionally,
Parambil et al. have examined nine CVD-IP patients with
a DAD pattern on surgical lung biopsy without known
etiology, and found that six of them had preexisting inter-
stitial pneumonia.9 Collectively, these results confirmed
that CVD-IP patients can develop AE.
The incidence of AE in IPF remains unknown. The
reported incidence varies widely, because there areFigure 2 Laboratory data of patients with CVD-IP at the onset of
ratio.differences in the definition of AE, as well as differences in
the populations studied. However, several prospective
randomized control or retrospective longitudinal cohort
studies have reported the likely incidence. Kim et al.
indicated a 1-year incidence of 8.5% in a retrospective
longitudinal cohort of 147 patients with biopsy-proven IPF.4
In a randomized controlled trial of pirfenidone, Azuma
et al. reported a 9-month incidence of 14.3% in 36 placebo-
treated patients.24 Taken together, the incidence of AE of
IPF was estimated to be in the range of 5e19% per year.5 In
CVD-IP, the present study revealed an overall incidence of
7.2%, with a mean 6.0 years follow-up, and a 1-year inci-
dence of 1.25%. Compared with the reported incidence of
AE of IPF, the incidence of CVD-IP appears to be lower.
Among the underlying CVD, AE was found exclusively in
patients with RA and pSS. Five of our six CVD-IP patients
with AE had RA (overall incidence, 20.0%; 1-year incidence,
2.58%), and the other patient had pSS. Consistent with our
observations, Park et al. described four CVD-IP patients
who developed AE, and found that most of them (75%) had
RA,13 although they did not mention the overall number forAE. Horizontal bars indicate mean values. P/F ratio, PaO2/FiO2
Figure 3 HRCT of AE of CVD-IP (Case 5). (A) Three months
before AE. Transverse thin-section CT of the lower lobe shows
mild reticular and cystic opacities in subpleural areas of the
lung. (B and C) Transverse and coronal thin-section CT of the
lower lobe at the onset of AE reveal superimposition of ground-
glass opacity spreading to both lungs.
Figure 4 Histopathology of AE of CVD-IP (Case 6). (A) Spec-
imen from surgical lung biopsy obtained before the onset of AE
shows temporary uniform fibrosis of the alveolar wall, with
mild infiltration of mononuclear cells (fibrotic NSIP) (hema-
toxylineeosin, 200). (B) Autopsy specimen reveals scattered
hyaline membranes lining thickened alveolar septa, with
interstitial edema (hematoxylineeosin, 400).
Table 4 Associated factors for AE development: univar-
iate Cox proportional hazards models.
Variables Hazard ratio 95% CI p Value
Lower Upper
Age, years 1.181 1.050 1.374 0.0037
Sex, female 0.764 0.283 1.744 0.5281
Smoking habit, yes 2.336 0.898 10.33 0.0844
CVD, RA 2.536 1.006 11.16 0.0484
Histology, NSIP 0.545 0.203 1.234 0.1452
VC, % 0.984 0.942 1.029 0.4681
DLco, % 1.054 0.975 1.208 0.1824
PaO2, Torr 1.008 0.924 1.111 0.8585
KL-6, U/ml 1.000 0.997 1.000 0.9314
AE, acute exacerbation; CI, confidence interval; CVD, collagen
vascular diseases; RA, rheumatoid arthritis; UIP, usual intersti-
tial pneumonia.
Acute exacerbation of collagen vascular diseases 851each CVD-IP. Collectively, these data suggest that patients
with CVD-IP develop AE less frequently than those with IPF,
and among CVD-IP, this condition is most common in RA.
Histologically, three of our six CVD-IP patients with AE
had a UIP pattern on surgical lung biopsy, and two had an
NSIP pattern, and the other had unclassifiable interstitialpneumonia. Originally, AE was reported to occur in UIP, but
recent studies have described this condition in interstitial
pneumonia with patterns other than UIP, such as the NSIP
pattern.10e14 So far, there are few data about the histology
of AE in CVD-IP. Parambil et al. have recently shown that
Table 5 Associated factors for AE development: multi-
variate Cox proportional hazards models.
Variables Hazard ratio 95% CI p Value
Lower Upper
Age, years 1.221 1.054 1.495 0.0052
CVD, RA 2.473 0.930 11.21 0.0716
AE, acute exacerbation; CI, confidence interval; CVD, collagen
vascular diseases; RA, rheumatoid arthritis.
852 T. Suda et al.acute respiratory deterioration in CVD-IP represented DAD
pattern on the underlying chronic fibrotic processes, such
as UIP and NSIP.9 As a result of severe respiratory failure,
the second surgical lung biopsy at the onset of AE could not
be performed in our patients, but an autopsy of one patient
with NSIP revealed a DAD pattern superimposed on a back-
ground of an NSIP pattern (Fig. 3). Collectively, these
results suggest that AE occurs in either UIP or NSIP patterns
of CVD-IP.
Radiological findings of our CVD-IP patients were
comparable to those of AE in IPF, as described previ-
ously.6,14,25 We found new, extensive ground-glass opacity
mostly with patchy air space consolidation, superimposed
on background reticular abnormality. In laboratory findings,
in addition to severe hypoxemia, marked elevations of
serum CRP and LDH levels were observed. Interestingly, the
serum levels of KL-6, a marker of interstitial pneumonia,
were strikingly increased in all patients tested at the onset
of AE. Similarly, in IPF, the serum levels of KL-6 were shown
to be elevated at AE, which suggests that this can be used
as a marker of this condition.26 A few data are available on
BAL findings of AE, and neutrophilia in BAL fluid has been
reported.2,4,8 We performed BAL in only one patient, and
marked neutrophilia was noted.
Little is known about the causative factors of AE of IPF.
Several studies have suggested that surgical lung biopsy
may cause AE.10,27 In agreement with those observations,
AE occurred immediately after surgical lung biopsy in one
patient with pSS-IP. In the remaining five patients,
however, the causative factors of this condition were not
determined. Interestingly, the activity of the underlying
CVD was stable in all patients at the onset of AE. This
suggests that development of AE is not associated with
deterioration of the underlying CVD, and can occur in
patients in a stable condition. In addition, no data are
available about the predictive factors for AE at the initial
diagnosis. We found that age and RA diagnosis were
significantly associated with AE using by univariate Cox’s
proportional hazards regression models. In addition, we
demonstrated that age remained significant in multivariate
Cox’s proportional hazards regression models, suggesting
that CVD-IP patients with higher ages are more likely to
develop AE.
Despite intensive anti-inflammatory and immunosup-
pressive therapies, the outcome associated with AE of CVD-
IP was poor in our patients. All patients were treated with
high-dose corticosteroids, and four of them also received
immunosuppressive agents, such as cyclophosphamide and
cyclosporine. However, five (83.3%) of our six patients died
of respiratory failure. This poor outcome of our CVD-IP
patients was similar to that in AE of IPF.3e6 Consistent withour observations, all four patients with AE of CVD-IP
reported by Park et al. died.13 These data suggest that AE
of CVD-IP is characterized by poor prognosis, which is
comparable to that of IPF.
There are several limitations to the present study. First,
this was a retrospective study, so there were selection and
recall biases. Second, the study population was restricted
to biopsy-proven cases, and may not accurately reflect the
general population of CVD-IP patients. Third, although this
study included a relatively large proportion of patients with
AE in CVD-IP, the sample size was still too small to deter-
mine the precise incidence and clinical characteristics of
this condition. Future studies will be required in a large
number of patients to confirm our observations.
In conclusion, the present study demonstrated that AE
occurred in CVD-IP with poor prognosis, and this condition
in CVD-IP closely resembled AE of IPF. In addition, AE is
most common in RA, and significantly associated with
higher ages. Although AE occurs less frequently in CVD-IP
than in IPF, attention should be made on this distinct
condition of CVD-IP.
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